Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to October 2014

Natural Extracts Lower Blood Pressure

October 2014

By Brandon Dewitte

Hypertension: The Silent Killer

Hypertension: The Silent Killer  

Olive leaf and celery seed extracts could not have been developed at a better time. Hypertension is quickly becoming a global epidemic.1 It is estimated that nearly 30% of adults around the globe have hypertension36—and that percentage climbs to 75% in some European nations.37 Even in the US, which has one of the highest rates of awareness of the disease, hypertension affects between nearly 30 to 50% of the population.37-39

Hypertension has long been known as the “silent killer.”8,40 Despite increased awareness and treatment of hypertension, it is estimated that more than 50% of people worldwide with high blood pressure are unaware of their condition, and only a minority have been able to achieve control of their blood pressure.41,42

If you’re unsure of your blood pressure levels, you should have them tested as soon as possible. Life Extension suggests that optimally, blood pressure should be maintained at 115/75 mm Hg. Blood pressure levels greater than 139/89 mm Hg should be treated right away. Talk to your doctor about possible treatments and consider adding the combination of celery seed extract and olive leaf extract to your treatment plan.

Rather than blindly assuming anything works, obtain an at-home blood pressure monitor to ensure that the drugs, nutrients, and lifestyle changes you are using to lower blood pressure are achieving optimal results.

Are You Predisposed To High Blood Pressure?

Many conditions cause or predispose a person to having hypertension.

Over 25% of US adults have metabolic syndrome, which includes hypertension as one of its defining features.47

Obesity, another component of metabolic syndrome, is a leading cause of high blood pressure, with 60 to 70% of hypertension in adults related to excess body fat, especially “central” obesity located around the abdomen.48 Being overweight or obese is associated with a significantly increased risk of hypertension compared with people of normal weight.49,50 Obesity imposes unusual stresses on the body’s self-regulatory mechanisms, among which are over-activation of the renin-angiotensin-aldosterone hormone system, which promotes fluid retention and boosts blood pressure.48,51

High levels of uric acid in the blood is directly related to hypertension. In one study, people with high uric acid levels were 2.6 times more likely to have high blood pressure than those with normal levels. And people with both high uric acid and obesity were more than 4.5 times as likely to be hypertensive, compared with normal-weight people with normal uric acid levels.50

Another cause of hypertension is obstructive sleep apnea (also called obstructive sleep apnea-hypopnea syndrome), in which a person’s breathing temporarily ceases or becomes very shallow during sleep.52 In one study, over 50% of people with the syndrome had hypertension compared with only 30% in controls.52

Regardless of the cause of hypertension, it is essential to treat it.

Figure 1: Blood Pressure Awareness And Treatment In America

While most Americans are aware of hypertension’s risks and many are receiving treatment, only a minority have been able to successfully control their blood pressure. The colored bars above represent the percentages of American adults who express awareness of the dangers of hypertension, those who are being treated for hypertension, and those who have their hypertension under control. Each color represents a different National Health and Nutrition Examination Survey (NHANES) study, which began in 1976.


Despite billions of dollars spent on drugs to lower blood pressure,43 Americans are still losing the battle to keep their hypertension under control. Even drugs that are effective at bringing down high blood pressure have uncomfortable, sometimes dangerous, side effects.

One of the most effective blood pressure drug combinations is an ACE inhibitor paired with a calcium channel blocker. But for those with early or mild-to-moderate hypertension (Stage I), ACE inhibition and calcium channel blocking may be accomplished with extracts from olive leaf and celery seed, respectively. Even those with more advanced cases of hypertension may be able to reduce their dosing of drugs by adding this nutrient combo.

Clinical studies show that each of these supplements alone is effective at significantly lowering blood pressure, generally without the adverse effects often associated with prescription medications. Using olive leaf and celery seed extract together is a powerful natural combination modeled on solid science.

If you have any questions on the scientific content of this article, please call a Life Extension® Wellness Specialist at 1-866-864-3027.


  1. Chockalingam A. World Hypertension Day and global awareness. Can J Cardiol. 2008 Jun;24(6):441-4.
  2. Leon MM, Mitu F. The clinical-epidemological study of drugs used to treat arterial hypertension and associated comorbidities. Rev Med Chir Soc Med Nat Iasi. 2013 Apr-Jun;117(2):488-94.
  3. Edelman DA, Paul RA. Does combination therapy with a calcium channel blocker and an ACE inhibitor have additive effects on blood pressure reduction? Int J Clin Pract. 2000 Mar;54(2):105-9.
  4. Available at: . Accessed July 16, 2014.
  5. Available at: . Accessed July 16, 2014.
  6. Hansen K, Adsersen A, Christensen SB, Jensen SR, Nyman U, Smitt UW. Isolation of an angiotensin converting enzyme (ACE) inhibitor from Olea europaea and Olea lancea. Phytomedicine. 1996 Mar;2(4):319-25.
  7. Jorge VG, Angel JR, Adrian TS, et al. Vasorelaxant activity of extracts obtained from Apium graveolens: possible source for vasorelaxant molecules isolation with potential antihypertensive effect. Asian Pac J Trop Biomed. 2013 Oct;3(10):776-9.
  8. Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, Schmidt A, Bradl B, Aydogan C. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytother Res. 2008 Sep;22(9):1239-42.
  9. Madhavi D, Kagan D, Rao V, Murray MT. A pilot study to evaluate the antihypertensive effect of a celery extract in mild to moderate hypertensive patients. Nat Med J. 2013;4(4):1-3.
  10. Kithas PA, Supiano MA. Practical recommendations for treatment of hypertension in older patients. Vasc Health Risk Manag. 2010;6:561-9.
  11. Gorostidi M, de la Sierra A. Combination therapy in hypertension. Adv Ther. 2013 Apr;30(4):320-36.
  12. Póvoa R, Barroso WS, Brandão AA, Jardim PC, Barroso O, Passarelli O Jr, et al. I Brazilian position paper on antihypertensive drug combination. Arq Bras Cardiol. 2014 Mar;102(3):203-10.
  13. Riva N, Lip GY. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker? Curr Pharm Des. 2013;19(21):3753-65.
  14. Wu HY, Huang JW, Lin HJ, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.
  15. Fyhrquist F, Metsärinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.
  16. Naidu MUR, Usha PR, Rao TRK, Shobha JC. Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. Postgrad Med J. 2000;76(896):350-53.
  17. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich). 2011 Sep;13(9):687-9.
  18. MacNab M, Mallows S. Safety profile of benazepril in essential hypertension. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV33-7; discussion IV51-5.
  19. Parzonko A, Czerwinska ME, Kiss AK, Naruszewicz M. Oleuropein and oleacein may restore biological functions of endothelial progenitor cells impaired by angiotensin II via activation of Nrf2/heme oxygenase-1 pathway. Phytomedicine. 2013 Sep 15;20(12):1088-94.
  20. Susalit E, Agus N, Effendi I, et al. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine. 2011 Feb 15;18(4):251-8.
  21. Khayyal MT, el-Ghazaly MA, Abdallah DM, Nassar NN, Okpanyi SN, Kreuter MH. Blood pressure lowering effect of an olive leaf extract (Olea europaea) in L-NAME induced hypertension in rats. Arzneimittelforschung. 2002;52(11):797-802.
  22. Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010 May;140(5):946-53.
  23. de Bock M, Derraik JG, Brennan CM, et al. Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PLoS One. 2013;8(3):e57622.
  24. Heyen BJ, Alsheikh MK, Smith EA, Torvik CF, Seals DF, Randall SK. The calcium-binding activity of a vacuole-associated, dehydrin-like protein is regulated by phosphorylation. Plant Physiol. 2002 Oct;130(2):675-87.
  25. Ko FN, Huang TF, Teng CM. Vasodilatory action mechanisms of apigenin isolated from Apium graveolens in rat thoracic aorta. Biochim Biophys Acta. 1991 Nov 14;1115(1):69-74.
  26. Peng Y, Sun J, Hon S, et al. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer’s disease. J Neurosci. 2010 Jun 16;30(24):8180-9.
  27. Moghadam MH, Imenshahidi M, Mohajeri SA. Antihypertensive effect of celery seed on rat blood pressure in chronic administration. J Med Food. 2013 Jun;16(6):558-63.
  28. Peng Y, Hu Y, Xu S, et al. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AbetaPP/PS1-Alzheimer’s transgenic mice. J Alzheimers Dis. 2012;29(2):379-91.
  29. Zhang L, Yu WH, Wang YX, et al. DL-3-n-Butylphthalide, an anti-oxidant agent, prevents neurological deficits and cerebral injury following stroke per functional analysis, magnetic resonance imaging and histological assessment. Curr Neurovasc Res. 2012 Aug;9(3):167-75.
  30. Chong Z, Feng Y. Protective effects of dl-3-n-butylphthalide on changes of regional cerebral blood flow and blood-brain barrier damage following experimental subarachnoid hemorrhage. Chin Med J (Engl). 1998 Sep;111(9):858-60.
  31. Chong Z, Feng Y. dl-3-n-butylphthalide reduces brain damage in mice with closed head injury. Chin Med J (Engl). 2000 Jul;113(7):613-6.
  32. Peng Y, Zeng X, Feng Y, Wang X. Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats. J Cardiovasc Pharmacol. 2004 Jun;43(6):876-81.
  33. Zhang Y, Wang L, Li J, Wang XL. 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther. 2006 Jun;317(3):973-9.
  34. Powanda MC, Rainsford KD. A toxicological investigation of a celery seed extract having anti-inflammatory activity. Inflammopharmacology. 2011 Aug;19(4):227-33.
  35. Peng Y, Xu S, Chen G, Wang L, Feng Y, Wang X. l-3-n-Butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharmacol Exp Ther. 2007 Jun;321(3):902-10.
  36. Angeli F, Reboldi G, Verdecchia P. Hypertension around the world: new insights from developing countries. J Hypertens. 2013; 31(7), 1358-61.
  37. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327-38.
  38. Egan BM, Zhao Y. Different definitions of prevalent hypertension impact: the clinical epidemiology of hypertension and attainment of healthy people goals. J Clin Hypertens (Greenwich). 2013 Mar;15(3):154-61.
  39. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3(8):e003423.
  40. Kim HS, Kim DG. Effect of long-term resistance exercise on body composition, blood lipid factors, and vascular compliance in the hypertensive elderly men. J Exerc Rehabil. 2013 Apr;9(2):271-7.
  41. Egan BM, Li J, Shatat IF, Fuller JM, Sinopoli A. Closing the gap in hypertension control between younger and older adults: National Health and Nutrition Examination Survey (NHANES) 1988 to 2010. Circulation. 2014 May 20;129(20):2052-61.
  42. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52.
  43. Available at: . Accessed July 18, 2014.
  44. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 Jul;34(28):2159-219.
  45. Lawler PR, Hiremath P, Cheng S. Cardiac target organ damage in hypertension: insights from epidemiology. Curr Hypertens Rep. 2014 Jul;16(7):446.
  46. Franklin SS. Hypertension in older people: part 1. J Clin Hypertens (Greenwich). 2006 Jun;8(6):444-9.
  47. Falkner B, Cossrow ND. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States. Curr Hypertens Rep. 2014 Jul;16(7):449.
  48. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens. 2010 Nov;23(11):1170-8.
  49. Available at: Accessed July 18, 2014.
  50. Han GM, Gonzalez S, Devries D. Combined effect of hyperuricemia and overweight/obesity on the prevalence of hypertension among US adults: result from the National Health and Nutrition Examination Survey. J Hum Hypertens. 2014 May 1.
  51. Becton LJ, Shatat IF, Flynn JT. Hypertension and obesity: epidemiology, mechanisms and clinical approach. Indian J Pediatr. 2012 Aug;79(8):1056-61.
  52. Wang Y, Li C, Feng L, Feng J, Cao J, Chen B. Prevalence of hypertension and circadian blood pressure variations in patients with obstructive sleep apnoea-hypopnoea syndrome. J Int Med Res. 2014 Mar 20;42(3):773-80.
  53. Fein A. ACE inhibitors worsen inflammatory pain. Med Hypotheses. 2009 Jun;72(6):757.